Metaterol is a beta-adrenoceptor agonist. It exerts sympathomimetic and broncholytic properties.

Metheptazine was studied as an analgesic agent.

Merisoprol Hg-197 is a radiopharmaceutical. It permits visualization of the spleen with reliability, speed, and simplicity. Splenic scintigraphy with merisoprol Hg-197 has proved useful in assessing splenic size, shape, and position, in demonstrating focal abnormalities, and in differentiating left upper abdominal masses.

SP-2086 H3PO4 (Retagliptin Phosphate), tetrahydro-imidazo[1,5-a] pyrazine derivative, is a competitive DPP-4 inhibitor innovated in China under development by Jiangsu Hengrui Medicine for the treatment of Type 2 diabetes. In completed phase II trials, retagliptin monotherapy or in combination with metformin significantly decreased the HbA1c level in type 2 diabetic patients. Two phase III trials for retagliptin monotherapy aCnd in combination with metformin, respectively, were ongoing in China. Jiangsu Hengrui Medicine withdrew its application from the Chinese FDA in April 2016 but is expected to refile the application.

Norleucine (L-norleucine) is a 2-aminohexanoic acid is an alpha-amino acid that is caproic acid substituted by an amino group at position 2. It derives from a hexanoic acid. It is used experimentally to study protein structure and function. Norleucine appears to inhibit bacterial growth due to incorporation into proteins in place of methionine, as the analogue inhibits methionine incorporation but does not significantly reduce its synthesis. L-norleucine had antiviral activity in thermophile. In vitro and in vivo assays revealed that L-norleucine significantly suppressed metastasis of gastric and breast cancer cells. L-norleucine interacted with hnRNPA2/B1 protein to inhibit the expressions of Twist1 and Snail, two inhibitors of E-cadherin, and promote the E-cadherin expression, leading to the inhibition of tumor metastasis.

Almorexant (ACT-078573) is an orally active dual orexin receptor antagonist that is being developed by Actelion Ltd, in collaboration with GlaxoSmithKline plc, for the treatment of primary insomnia. Almorexant is a first-in-class compound that targets the orexin system, which plays a key role in wake promotion and stabilization; In January 2011, GlaxoSmithKline (GSK) and Actelion Ltd announced that clinical development of Phase III of almorexant has been discontinued. This decision follows a review of data from additional clinical studies, which were conducted to further establish the clinical profile of almorexant, including the tolerability profile.

Cinaproxen is naproxen derivative developed by Nicox S.A. for oxidative stress prevention and treatment.